全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
ISRN Allergy  2014 

Atopic Dermatitis: Natural History, Diagnosis, and Treatment

DOI: 10.1155/2014/354250

Full-Text   Cite this paper   Add to My Lib

Abstract:

Atopic dermatitis is an inflammatory skin disease with early onset and with a lifetime prevalence of approximately 20%. The aetiology of atopic dermatitis is unknown, but the recent discovery of filaggrin mutations holds promise that the progression of atopic dermatitis to asthma in later childhood may be halted. Atopic dermatitis is not always easily manageable and every physician should be familiar with the fundamental aspects of treatment. This paper gives an overview of the natural history, clinical features, and treatment of atopic dermatitis. 1. Definition Atopic dermatitis is a common, chronic, relapsing, inflammatory skin disease that primarily affects young children. Atopy is defined as an inherited tendency to produce immunoglobulin E (IgE) antibodies in response to minute amounts of common environmental proteins such as pollen, house dust mites, and food allergens. Dermatitis derives from the Greek “derma,” which means skin, and “itis,” which means inflammation. Dermatitis and eczema are often used synonymously, although the term eczema is sometimes reserved for the acute manifestation of the disease (from Greek, ekzema, to boil over); here, no distinction is made. Over the years, many other names have been proposed for the disease, for instance, prurigo Besnier (Besnier’s itch), named after the French dermatologist Ernest Besnier (1831–1909). Allergic sensitization and elevated immunoglobulin E (IgE) are present in only about half of all patients with the disease, and therefore atopic dermatitis is not a definitive term. 2. Epidemiology Atopic dermatitis affects about one-fifth of all individuals during their lifetime, but the prevalence of the disease varies greatly throughout the world [1]. In several so-called industrialised countries, the prevalence increased substantially between 1950 and 2000 so much that many refer to as the “allergic epidemic.” However, current indications point to eczema symptoms having levelled off or even having decreased in some countries with a formerly very high prevalence, such as the United Kingdom and New Zealand. This indicates that the allergic disease epidemic is not increasing continually worldwide. Nevertheless, atopic dermatitis remains a serious health concern, and in many countries, particularly in the developing world, the disease is still very much on the rise. 2.1. Natural History Around 50% of all those with atopic dermatitis develop symptoms within their first year of life, and probably as many as 95% experience an onset below five years of age [2]. Around 75% with childhood onset of the disease

References

[1]  M. I. Asher, S. Montefort, B. Bj?rkstén et al., “Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys,” The Lancet, vol. 368, no. 9537, pp. 733–743, 2006.
[2]  H. C. Williams, “Atopic dermatitis,” New England Journal of Medicine, vol. 352, no. 22, pp. 2314–2366, 2005.
[3]  J. M. Spergel, “From atopic dermatitis to asthma: the atopic march,” Annals of Allergy, Asthma and Immunology, vol. 105, no. 2, pp. 99–106, 2010.
[4]  A. J. Lowe, J. B. Carlin, C. M. Bennett et al., “Do boys do the atopic march while girls dawdle?” Journal of Allergy and Clinical Immunology, vol. 121, no. 5, pp. 1190–1195, 2008.
[5]  S. F. Thomsen, C. S. Ulrik, K. O. Kyvik et al., “Importance of genetic factors in the etiology of atopic dermatitis: a twin study,” Allergy and Asthma Proceedings, vol. 28, no. 5, pp. 535–539, 2007.
[6]  C. N. A. Palmer, A. D. Irvine, A. Terron-Kwiatkowski et al., “Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis,” Nature Genetics, vol. 38, no. 4, pp. 441–446, 2006.
[7]  A. D. Irvine, W. H. I. McLean, and D. Y. M. Leung, “Filaggrin mutations associated with skin and allergic diseases,” New England Journal of Medicine, vol. 365, no. 14, pp. 1315–1327, 2011.
[8]  J. Douwes and N. Pearce, “Asthma and the westernization ‘package’,” International Journal of Epidemiology, vol. 31, no. 6, pp. 1098–1102, 2002.
[9]  D. P. Strachan, “Hay fever, hygiene, and household size,” British Medical Journal, vol. 299, no. 6710, pp. 1259–1260, 1989.
[10]  J.-F. Bach, “The effect of infections on susceptibility to autoimmune and allergic diseases,” New England Journal of Medicine, vol. 347, no. 12, pp. 911–920, 2002.
[11]  E. von Mutius, “Maternal farm exposure/ingestion of unpasteurized cow's milk and allergic disease,” Current Opinion in Gastroenterology, vol. 28, pp. 570–576, 2012.
[12]  S. Hong, W. J. Choi, H. J. Kwon, Y. H. Cho, H. Y. Yum, and D. K. Son, “Effect of prolonged breast-feeding on risk of atopic dermatitis in early childhood,” Allergy and Asthma Proceedings, vol. 35, pp. 66–70, 2014.
[13]  L. Hammer-Helmich, A. Linneberg, S. F. Thomsen, and C. Glümer, “Association between parental socioeconomic position and prevalence of asthma, atopic eczema and hay fever in children,” Scandinavian Journal of Public Health, vol. 42, pp. 120–127, 2014.
[14]  K. Eyerich and N. Novak, “Immunology of atopic eczema: overcoming the Th1/Th2 paradigm,” Allergy, vol. 68, pp. 974–982, 2013.
[15]  A. de Benedetto, A. Kubo, and L. A. Beck, “Skin barrier disruption: a requirement for allergen sensitization,” Journal of Investigative Dermatology, vol. 132, no. 3, pp. 949–963, 2012.
[16]  J. M. Hanifin, K. D. Cooper, V. C. Ho et al., “Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association ‘Administrative Regulations for Evidence-Based Clinical Practice Guidelines’,” Journal of the American Academy of Dermatology, vol. 50, pp. 391–404, 2004.
[17]  H. C. Williams, P. G. J. Burney, R. J. Hay et al., “The U.K. Working party's diagnostic criteria for atopic dermatitis—I. Derivation of a minimum set of discriminators for atopic dermatitis,” British Journal of Dermatology, vol. 131, no. 3, pp. 383–396, 1994.
[18]  J. F. Stalder, A. Taieb, D. J. Atherton et al., “Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis,” Dermatology, vol. 186, no. 1, pp. 23–31, 1993.
[19]  J. M. Hanifin, M. Thurston, M. Omoto, R. Cherill, S. J. Tofte, and M. Graeber, “The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis,” Experimental Dermatology, vol. 10, no. 1, pp. 11–18, 2001.
[20]  F. J. Bath-Hextall, A. J. Birnie, J. C. Ravenscroft, and H. C. Williams, “Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review,” British Journal of Dermatology, vol. 163, no. 1, pp. 12–26, 2010.
[21]  J. Ring, A. Alomar, T. Bieber, et al., “Guidelines for treatment of atopic eczema (atopic dermatitis)—part I,” Journal of the European Academy of Dermatology and Venereology, vol. 26, pp. 1045–1060, 2012.
[22]  E. L. Simpson, “Atopic dermatitis: a review of topical treatment options,” Current Medical Research and Opinion, vol. 26, no. 3, pp. 633–640, 2010.
[23]  G. Ricci, A. Dondi, and A. Patrizi, “Useful tools for the management of atopic dermatitis,” American Journal of Clinical Dermatology, vol. 10, no. 5, pp. 287–300, 2009.
[24]  H. C. Williams, “Established corticosteroid creams should be applied only once daily in patients with atopic eczema,” British Medical Journal, vol. 334, no. 7606, article 1272, 2007.
[25]  M. M. Y. El-Batawy, M. A.-W. Bosseila, H. M. Mashaly, and V. S. G. A. Hafez, “Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis,” Journal of Dermatological Science, vol. 54, no. 2, pp. 76–87, 2009.
[26]  G. Ricci, A. Dondi, A. Patrizi, and M. Masi, “Systemic therapy of atopic dermatitis in children,” Drugs, vol. 69, no. 3, pp. 297–306, 2009.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413